O.Gautschi and L.Bubendorf discourse on the presence of RET aberrations in NSCLC; explain current diagnostic techniques and future screening possibilities; and call for more trials to validate use of promising targeted drugs, sending patients to active centres for broad testing.
Related Videos In Lung Cancer
Ross Camidge: Brigatinib for Adult Patients With ALK+ Metastatic Non-small Cell Lung Cancer
touchONCOLOGY were delighted to speak to Ross Camidge, University of Colorado Cancer Center, to discuss the recent FDA approved of brigatinib for adult patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer. Questions 1. What are the unmet needs in the treatment of patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer? (0:06) […]
Jared Weiss, ASCO20: Trilaciclib in Patients with Small Cell Lung Cancer
touchONCOLOGY were joined by Jared Weiss, Lineberger Comprehensive Cancer Center, to discuss the data presented at the ASCO20 Virtual Meeting on myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer. Questions 1. Could you give us a brief overview about the aims and design of the Phase II […]
Raffaele Califano, ESMO 2019 – FLAURA study in NSCLC
Our Editorial Board member, Raffaele Califano (The Christie NHS Foundation Trust) joined us at ESMO 2019 to highlight results from the FLAURA study in NSCLC (NCT02296125). Questions 1. Please describe the FLAURA trail and its reported results? (0:04) 2. Clinically, what impact do you think osimertinib will have over existing standard of care for patients […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!